LIA
BBIO icon

Limestone Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Limestone Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,000
Closed -$302K – 547
2025
Q2 		$302K Buy
+7,000
New +$255K 0.03% 320

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Limestone Investment Advisors's BBIO Position: Q3 2025 in Review

Limestone Investment Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 7,000 shares — an estimated $302K sold.

Limestone Investment Advisors first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $302K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Limestone Investment Advisors reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Limestone Investment Advisors sold 7,000 BridgeBio Pharma shares in Q3 2025, an estimated $302K.
  • Limestone Investment Advisors first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
  • Limestone Investment Advisors's BridgeBio Pharma position peaked at $302K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Limestone Investment Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.